Translational cancer research – a coherent cancer research continuum

Ringborg, Ulrik

doi:10.1002/1878-0261.12450

Cited by 17 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include the following: (a) cancer biology (basic and preclinical research); (b) identification of healthy individuals at risk of developing cancer (primary prevention); (c) early cancer detection (secondary prevention); (d) cancer patient treatment and research (clinical); and (e) support for cancer survivors (tertiary prevention). Assessing progress in these areas requires different methodological approaches [4][5][6]. Outcomes research for both therapeutic interventions and the effectiveness of public health interventions and health services will be critical for progress assessment.…”

Section: Introductionmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

Self Cite

View full text Add to dashboard Cite

A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer researchcare-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidencebased advice.

show abstract

Section: Introductionmentioning

confidence: 99%

Towards a cancer mission in Horizon Europe: recommendations

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…This raises the question how we best organise this continuum of basic, preclinical and clinical research in order to catalyse these developments. (Ringborg, ). Institutions in which different disciplines closely collaborate and investigators are able to swiftly test new concepts and validate those in clinical trials seem best positioned for this.…”

Section: Introductionmentioning

confidence: 97%

“…The fact that cancer treatments almost invariably have substantial side effects means there is an urgent need to scrutinise the effectiveness of treatments and the quality-of-life consequences for patients, as well as the burden for the healthcare system, including the associated cost. This raises the question how we best organise this continuum of basic, preclinical and clinical research in order to catalyse these developments (Ringborg, 2019). Institutions in which different disciplines closely collaborate and investigators are able to swiftly test new concepts and validate those in clinical trials seem best positioned for this.…”

Section: Introductionmentioning

confidence: 99%

Quality‐assured research environments for translational cancer research

Berns

2019

Molecular Oncology

View full text Add to dashboard Cite

In order to secure high‐quality cancer care for increasing numbers of cancer patients in the upcoming decades, the complete continuum of cancer research and cancer care needs a thorough overhaul, with more emphasis on prevention and early detection, and a greater focus on the development of innovative treatments that are also scrutinised for effectiveness and quality‐of‐life aspects. Therefore, under‐resourced research areas, such as primary prevention, early diagnosis/secondary prevention (Song et al ., 2018 ; Wild et al ., 2015 ) and outcomes research (Cavers et al ., 2017 ), should be given more emphasis, whereas basic, preclinical and clinical cancer research requires more innovation and effective collaboration to develop more effective treatments at an affordable cost. Innovative collaborative research in this translational trajectory requires the participation of well‐resourced and well‐organised institutions that are committed to high scientific and ethical standards. Offering focused funding to distinct segments of this research continuum concomitant with incentives to aspire to high‐quality standards is the most effective route to achieve these goals. Therefore, a rigorous quality assessment system for institutions operating in this research continuum is a high priority.

show abstract

mentioning

confidence: 97%

“…Ringborg begins a series of discussions on research issues by defining translational cancer research as a coherent cancer research continuum and proceeds to highlight the need to bridge research components in therapeutics and prevention to facilitate/accelerate the conversion of research discoveries into clinical/prevention applications. Spanning the cancer research/care continuum is deemed essential to a successful mission (Ringborg, 2019). Eggermont et al present Cancer Core Europe, a legal, bottom-up consortium of seven large cancer research centresmost of them Comprehensive Cancer Centres (CCCs)from different countries, which are committed to sharing expertise, resources, patients, and information.…”

mentioning

confidence: 99%